Tapering Depakote (Valproate) ER in Bipolar Disorder
For a patient with bipolar disorder stable on 1000 mg nightly Depakote ER, discontinuation should only be considered after at least 2 years of mood stability, with a gradual taper reducing the dose by approximately 25% every 2 weeks under close clinical monitoring, recognizing that this carries significant relapse risk. 1
When to Consider Discontinuation
Maintenance treatment with valproate should continue for at least 2 years after the last bipolar episode. 1 The decision to discontinue after this period should preferably be made in consultation with a mental health specialist, weighing:
- Years of stability (several years of complete remission increases candidacy for discontinuation) 1
- Individual relapse risk (history of frequent episodes, rapid cycling, or severe episodes suggests higher risk) 1
- Patient preference and quality of life considerations (adverse effects, desire for medication-free trial) 1
- Family input and support system availability 1
Recommended Taper Schedule
Reduce the valproate dose by approximately 25% every 2 weeks. 2 For a patient on 1000 mg nightly:
- Week 1-2: Reduce to 750 mg nightly (25% reduction) 2
- Week 3-4: Reduce to 500 mg nightly (50% of original dose) 2
- Week 5-6: Reduce to 250 mg nightly (75% reduction) 2
- Week 7: Discontinue completely 2
This yields a total taper duration of approximately 6-8 weeks. 2 The speed and duration of withdrawal can be highly variable and should be adjusted based on emergence of mood symptoms. 2
Critical Monitoring During Taper
Monitor the patient weekly during the taper period for: 3
- Early warning signs of mood episode recurrence (sleep disturbance, irritability, increased energy, depressive symptoms) 3
- Suicidal ideation or worsening mood instability 3
- Changes in functioning (work, social, family domains) 1
If any prodromal symptoms emerge, immediately slow or halt the taper and consider returning to the previous stable dose. 2
Important Clinical Pitfalls
Do not abruptly discontinue valproate, as this significantly increases relapse risk and may precipitate a severe mood episode. 2 The FDA label specifically warns against abrupt discontinuation in patients taking antiepileptic drugs to prevent major seizures due to risk of status epilepticus, and this principle of gradual withdrawal applies equally to psychiatric indications. 2
Recognize the high relapse risk: Even with gradual tapering, patients discontinuing mood stabilizers face substantially elevated relapse rates. 4 One study in adolescents found high relapse rates even when lithium was continued, raising questions about maintaining remission after stabilization. 4
Ensure adequate psychosocial support is in place before attempting discontinuation, including psychoeducation for the patient and family about early warning signs of relapse. 1
Alternative to Complete Discontinuation
If the goal is to reduce medication burden or side effects rather than complete cessation, consider dose reduction to the minimum effective maintenance level (often lower than acute treatment doses) rather than full discontinuation. 5 Japanese data suggest maintenance valproate levels of approximately 40-52 mcg/mL may be sufficient for prophylaxis in some patients, corresponding to lower doses than used acutely. 5
Maintain regular follow-up for at least 6-12 months after successful taper completion, as late relapses can occur even after initially successful discontinuation. 1